MedTrace Logo

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

NCT06145360 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-04-08

No results posted yet for this study

Summary

The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.

Conditions

  • Glucose Metabolism Disorders
  • Diabetes Mellitus, Type 2
  • Hypoglycemic Agents
  • Empagliflozin

Interventions

DRUG

Empagliflozin 10 MG

the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM

DRUG

Insulin+Metformin+DPP4 inhibitor (DPP4I)

Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care

Sponsors & Collaborators

  • Horizon Pharmaceutical Pvt Ltd

    collaborator UNKNOWN

  • SINA Health Education and Welfare Trust

    lead OTHER

Principal Investigators

  • Hina Sharif, Pharm-D,MSPH · SINA Health Education & Welfare Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-03-01
Completion
2024-03-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06145360 on ClinicalTrials.gov